Last reviewed · How we verify

NCT04066582

Early Feasibility Study: Application of OCT Imaging in Dermatology

Completed Last updated 22 April 2021
What this trial tests

trial testing ApolloVue™ S100 image system, Viper1-S003 in Skin Diseases in 123 participants. Completed in 2 October 2019.

Timeline
29 January 2018
Primary endpoint
2 October 2019
2 October 2019

Quick facts

Lead sponsorMackay Memorial Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment123
Start date29 January 2018
Primary completion2 October 2019
Estimated completion2 October 2019
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

Mackay Memorial Hospital

Who can join

20 and older, any sex, with Skin Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Optical coherence tomography (OCT) is an established medical imaging technique that uses light to capture biological images from within optical scattering media (e.g., biological tissue). A high-resolution OCT has the characteristics of non-invasive, label-free, real-time, cellular resolution with high tissue penetration depth that are highly valuable for clinical use. AMO has developed an in-vivo OCT scanning system prototype based on the clinical needs and potential applications. This study is designed as an early feasibility study aiming for validation of AMO's in-vivo OCT scanning system in dermatology through collaboration with Mackay Memorial Hospital. The OCT can provide cellular-resolution (\<1μm in lateral and axial directions) images which can be utilized to identify organelles. A high-resolution OCT has the characteristics of non-invasive, label-free, real-time, cellular resolution with high tissue penetration depth that are highly valuable for clinical use. The proposed scenario in this study is to collecting OCT images of skins with suspicious lesion including tumor, inflammatory diseases or pigment alteration as well as normal skin by using AMO's in vivo OCT imaging system. By using traditional pathological biopsy images or dermoscopic images as gold standard references, investigators will try to identify different characteristics in OCT images of skin with suspicious lesion including tumor, inflammatory diseases, or pigment alteration as well as normal skins.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ApolloVue™ S100 image system, Viper1-S003

Trials testing the same drug.

Other recruiting trials for Skin Diseases

Currently open trials in the same condition.

Other Mackay Memorial Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04066582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing